روند روزانه سهام شرکت
Achillion Pharmaceuticals, Inc.
این نمودار بصورت روزانه به روز رسانی می گردد
|نام شرکت||نماد||سرمایه (میلیون دلار)||کشور||عرضه اولیه||زیر مجموعه|
|Achillion Pharmaceuticals, Inc.||ACHN||۵۶۲/۰۹||United States||۲۰۰۶||
We are a science-driven, patient-focused biopharmaceutical company seeking to leverage our believed strengths across the continuum from discovery through commercialization by discovering and developing small molecule therapeutics to meet the needs of patients with infectious and complement-mediated diseases. Our current focus is on our complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is a part of the human innate immune system and is believed to comprise three pathways, the alternative pathway, the lectin pathway and the classical pathway. We are advancing novel small molecules from this platform which will initially target complement factor D, an essential protein within the amplification loop of the alternative pathway.